Bone marrow failure is a consistent feature of Fanconi anemia (FA) but it is not known whether the bone marrow failure is a direct and specific result of the inherited mutation or a consequence of accumulated stem cell losses resulting from nonspecific DNA damage. We tested the hypothesis that the protein encoded by the FA group C complementing gene (FACC) plays a regulatory role in hematopoiesis. We exposed normal human lymphocytes, bone marrow cells, endothelial cells, and fibroblasts to an antisense oligodeoxynucleotide (ODN) complementary to bases -4 to +14 of FACC mRNA. The mitomycin C assay demonstrated that the antisense ODN, but not missense or sense ODNs, repressed FACC gene expression in lymphocytes. Treatment with the antisense ODN substantially reduced, in a sequence-specific fashion, cytoplasmic levels of FACC mRNA in bone marrow cells and lymphocytes. Escalating doses of antisense ODN increasingly inhibited clonal growth of erythroid and granulocyte-macrophage progenitor cells but did not inhibit growth of fibroblasts or endothelial cells. The antisense ODN did not inhibit growth factor gene expression by low density bone marrow cells or marrow-derived fibroblasts. We conclude that, while the FACC gene product plays a role in defining cellular tolerance to cross-linking agents, it also functions to regulate growth, differentiation, and/or survival of normal hematopoietic progenitor cells.
Introduction
Bone marrow failure is a consistent feature of Fanconi anemia (FA) but it is not known whether the bone marrow failure is a direct and specific result of the inherited mutation or a consequence of accumulated stem cell losses resulting from nonspecific DNA damage. We tested the hypothesis that the protein encoded by the FA group C complementing gene (FACC) plays a regulatory role in hematopoiesis. We exposed normal human lymphocytes, bone marrow cells, endothelial cells, and fibroblasts to an antisense oligodeoxynucleotide (ODN) complementary to bases -4 to +14 of FACC mRNA. The mitomycin C assay demonstrated that the antisense ODN, but not missense or sense ODNs, repressed FACC gene expression in lymphocytes. Treatment with the antisense ODN substantially reduced, in a sequence-specific fashion, cytoplasmic levels of FACC mRNA in bone marrow cells and lymphocytes. Escalating doses of antisense ODN increasingly inhibited clonal growth of erythroid and granulocyte-macrophage progenitor cells but did not inhibit growth of fibroblasts or endothelial cells. The antisense ODN did not inhibit growth factor gene expression by low density bone marrow cells or marrow-derived fibroblasts. We conclude that, while the FACC gene product plays a role in defining cellular tolerance to cross-linking agents, it also functions to regulate growth, differentiation, and/or survival of normal hematopoietic progenitor cells. (J. Clin. Invest. 1994 . 94:846-852.) Key words: hematopoiesis * antisense oligonucleotides -DNA damage * chromosome instability * cross-linking agent Fanconi anemia (FA)1 is an autosomal recessive disorder characterized by cellular hypersensitivity to agents that damage DNA, bone marrow failure, diverse congenital anomalies, and a marked increase in the incidence of acute myelogenous leukemia (1, 2) . Diagnostically, the sine qua non of this disorder is hypersensitivity of FA cells to the clastogenic effects of DNA cross-linking agents such as diepoxybutane and mitomycin C (3, 4) . This disorder is genetically heterogeneous, with four different complementation groups having been identified by somatic cell hybrid analysis (5) . While the cDNA for group C has been cloned, sequenced, and mapped to chromosome 9q22.3 (6, 7) , there is no substantial amino acid sequence homology with any known gene family and, to date, the function of the gene product is unknown (6) . This is particularly true for the potential role of the FACC protein in hematopoiesis. Clearly, the FACC gene product functions to either facilitate interstrand cross-link repair (directly or indirectly) (8) (6, 7) and the formal demonstration that the inherited mutation is sufficient to confer the mitomycin C-sensitive phenotype (9) have enabled us to test directly the hematopoietic activity of the FACC gene product using specific antisense oligonucleotides. These studies were designed to test the hypothesis that the FACC gene product plays a direct permissive role in growth and/or differentiation of hematopoietic progenitor cells. Mitomycin C assay. Human peripheral blood mononuclear leukocytes were isolated from normal volunteers using centrifugation on Ficoll-Hypaque (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) as described previously (10) and resuspended at a concentration of 4.0 x 106 cells/ml. Ficoll-Hypaque-separated lymphocytes from two normal volunteers (50 and 24 yr of age) were cultured in a microwell culture plate in 1 ml of RPMI 1640 medium supplemented with 10% "high-heat" inactivated (45 min at 660C to efficiently inactivate DNases known to degrade ODNs in vitro [11] ) FCS (Hyclone Laboratories, Logan, UT), 4 jIM L-glutamine, and 1% phytohemagglutinin. Antisense, missense, and sense ODNs (20 jOM) were added to different wells at the same time mitomycin C was added according to methods described previously (12) . In certain experiments, total cytoplasmic RNA was extracted 6 h after the addition of ODNs (see below). After 4 d, metaphase preparations (13) were made, and viable cell counts were performed using a hemocytometer and trypan blue staining. 50 (donor 1) or 100 (donor 2) metaphases were scored (for breaks and radial forms) for each experimental condition. A radial was defined as a chromatid interchange, in which chromatids remained paired in mitosis, giving rise to a structure with multiple arms.
Treatment of bone marrow cells with ODNs. Paid normal human volunteers, after having given signed informed consent, provided bone marrow cells from the iliac crest. In certain experiments, low density bone marrow mononuclear cells (14) were depleted of adherent cells and T lymphocytes as described previously (14) (Fig. 2) or peripheral blood cells (not shown).
Antisense ODN inhibits CFU-E-, BFU-E-, and CFU-GM-derived colony growth. Bone marrow cells from six normal volunteers were exposed to multiple doses of antisense and sense ODNs for 24 h and were then replated in methylcellulose in the presence of hematopoietic growth factors. Exposure of marrow cells to the antisense molecule specifically, significantly, and in a dose-related fashion inhibited clonal growth of erythroid (CFU-E and BFU-E) and myeloid (CFU-GM) progenitor cells (Fig. 3) . Phosphorothioate-modified oligonucleotides were also used in some experiments, the antisense versions (but not the sense strands) of which effected equivalent suppression of clonal growth (not shown). Although some investigators have observed that exposure of FA cells to atmospheric oxygen or hyperoxia inhibits growth in vitro (20) (21) (22) , parallel culture studies performed at both 0.1 or 5 and 20% 02 indicated that the gene product is required for optimal colony growth at all oxygen tensions (not shown).
The inhibitory effect of the antisense ODN was noted on bone marrow cells depleted of adherent cells and T lymphocytes (Table II) . Likewise, pretreatment with the antisense ODN inhibited BFU-E-and CFU-GM-derived colony growth from bone marrow cells which had been highly enriched for cells expressing the integral membrane protein CD34 (the proportion of CD34 + cells before and after enrichment was 4.1 and 69.7%, respectively) and then cultured at very low cell density (5 X 102 cells/ml, Table II ). CFU-E-derived colony growth was not observed in the cultures of CD34+ cells (Table II) , consistent with the observation that CFU-Es do not express CD34 (23) .
Antisense ODN does not suppress growth factor gene expression. Our observations with hematopoietic progenitor cellenriched marrow cell populations (Table II) are compatible with the view that the antisense ODN directly inhibited progenitor cell replication and/or differentiation. However, some auxiliary cells usually contaminate even highly enriched progenitor cell populations from human marrow. Therefore, the suppression of clonal hematopoiesis also might have resulted from functional inhibition of the few colony-stimulating factor-producing auxiliary cells that remained in these cultures. Therefore, we tested this notion directly by measuring constitutive and IL-1-induced synthesis of GM-CSF, G-CSF, and IL-6 by human low density bone marrow cells or bone marrow fibroblasts cultured with and without ODNs. We chose to assay these three factors because they enhance clonal growth of progenitor cell types examined in this study. Neither sense nor antisense sequences inhibited uninduced or IL-1-induced growth factor gene expression (Table III) Figure 1 . Radial forms and broken chromosomes result from exposure of normal lymphocytes to antisense FACC ODN, PHA, and mitomycin C. Radial forms (large arrows) and breaks (small arrows) are similar to those seen 4 in lymphocyte culture from Fanconi anemia patients treated with mitomycin C. Similar results were seen in experiments using lymphocytes from a second normal volunteer (Table I ).
ODNs to enter or function within endothelial cells or fibroblasts because we have shown previously that antisense oligonucleotides are taken up by these cells and efficiently repress gene expression (11, 24) .
Discussion
The nearly universal occurrence of bone marrow failure and the high risk of acute nonlymphocytic leukemia in children with FA (2, 25, 26) suggest that hematopoietic tissue is uniquely sensitive to FA mutations. Clearly, the high frequency of cytogenetic defects in bone marrow cells of FA children with myelo- cell RNA and FACCspecific primers. The lower panel shows the 598-base GAPDH amplification product using the same amount of mRNA with GAPDH-specific primers. Lane (26, 27) confirms that acquired defects in somatic cells are an important element of multistep leukemogenesis, but the nature of early bone marrow failure in FA patients is unknown. Indeed, early marrow failure may represent a condition favoring the very earliest steps in leukemogenesis. To clarify the relationships that exist between bone marrow failure and leukemogenesis in this population of patients, the function of the FA gene product must be determined.
It is possible that bone marrow failure is only the result of nonspecific hematopoietic injury resulting from accumulated DNA damage. However, that the products of one or more of the FA complementing genes plays a regulatory role in growth of hematopoietic cells is also a plausible, albeit not necessarily exclusive, explanation. These alternatives cannot be tested by studying hematopoietic cells from patients with FA because any observed aberrancies might derive either from a specific (inherited) loss of hematopoietic function or from nonspecific damage to hematopoietic stem cells and/or bone marrow stromal cells that support hematopoiesis. Indeed, some stromal cell abnormalities have been described in FA cells, including abnormal production of hematopoietic growth factors (28) (29) (30) , but it is likely that these are acquired because such defects are not consistently found in affected patients in multiplex families (30) .
In this study, we have shown that pretreatment of normal lymphocytes with the FACC antisense ODN induces hypersensitivity to the chromosome-damaging effects of mitomycin C ( Fig. 1 these cells, possibly by an RNase H-dependent mechanism (11, 31, 32) . Pretreatment with the FACC antisense ODN inhibits clonal growth of erythroid and granulomonocytic progenitor cells in a concentration-dependent, sequence-specific fashion (Fig. 3) . The apparently greater sensitivity of CFU-GM-derived colony growth (Fig. 3 B) , compared with CFU-E-and BFU-E-derived colony growth (Fig. 3, C and D) , could reflect inherent differences between the progenitor cell types in their relative sensitivity to similar degrees of FACC repression, the efficiency with which they internalize ODNs (33), their relative RNase H levels; or any of a number of other possibilities. An explanation for why inhibition of colony growth was only partial even at maximal ODN concentrations (Fig. 3) (34) . Further study will be required to answer these questions. Pretreatment with the FACC antisense ODN inhibited subsequent colony growth in cultures of progenitor-enriched marrow cells (Table II) , including a CD34' cell-enriched population which displayed 9-10% plating efficiency even when cultured at very low cell density (500 cells/ml). Moreover, the FACC antisense ODN does not inhibit constitutive or IL-1-induced GM-CSF, G-CSF, or IL-6 production by low density marrow cells or bone marrow-derived fibroblasts (Table HII) . (36) (37) (38) (39) , also play functional roles in nonhematopoietic cells (40) (41) (42) (43) . The specific loss-of-function approach described here will permit a more specific clarification of the precise role of the FACC gene product in growth and development of both hematopoietic and nonhematopoietic cells.
